Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Regeneron
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Regeneron
-
Prikvačeni tweet
With @Society4Science, we’re introducing the 2020#RegeneronSTS finalists! These bright young minds are the top 40 contenders from nearly 2,000 applicants with research projects focused on beehive protection, clean water and greenhouse light. Read on: http://bit.ly/2tGzhkX .pic.twitter.com/8twuGzZDnaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tune in for our
$REGN Q4 earnings call at 8am ET today: http://bit.ly/2S4bjcT pic.twitter.com/ivBnDhKXAj
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
There are many steps taken to create our medicines. The
#RegeneronIOPS team uses cutting-edge technology to develop, optimize, validate and license the complex manufacturing processes required to produce life-changing medicines for people around the world.
pic.twitter.com/XLBUFwZalaHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our colleagues are dedicated to making a difference for patients. This
#WorldCancerDay
, Israel Lowy, SVP of Translational Science & Clinical Oncology, explains how we are researching new ways to use bispecific #antibodies: http://bit.ly/2GU0CmL pic.twitter.com/3WzoR7pNPt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don’t miss our Q4 earnings call on Thursday at 8 am ET: http://bit.ly/380Hyzg .
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Announcing our expanded collaboration with
@HHSGov to develop new potential antibody medicines for the novel#coronavirus. Learn more: http://bit.ly/2OrUgz2 .pic.twitter.com/PqbbFPMI3I
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
#ScienceWordofToday is… pathogen: a disease-causing microorganism, such as a virus or bacteria.pic.twitter.com/HrQcCdIE0VHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ICYMI: The new#RegeneronDNALC is an interactive educational center equipped with two state-of-the-art teaching labs. We hope to inspire future generations and look forward to hosting local school field trips! Learn more:http://bit.ly/2GEUEG3Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Drew Murphy, our EVP of Research, discusses with
@USAToday how scientists are harnessing the body’s natural processes to create novel antibody medicines.https://twitter.com/USATODAY/status/1216761070494326789 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Charlie’s panel discussion was a continuation of his work evaluating the utility of the polygenic risk score for cardiovascular patients, as noted in his November 2019 paper from
@CircAHAPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
This
#WorldPrivacyDay, we asked our Chief Privacy Officer, Ericka Watson, what she wants everyone to know about#privacy.pic.twitter.com/vnibx9uPjK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Not all
#antibody medicines are created equal. Our deep scientific expertise allows us to develop new technologies to help discover novel antibody medicines. Learn more from our scientists: http://bit.ly/3aRNpIG pic.twitter.com/gumLBmcKWD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Announcing w/
@SanofiGenzyme: the FDA has accepted for priority review the sBLA for our medicine for children aged 6-11 years with inadequately controlled moderate-to-severe#atopicdermatitis. Read more: http://bit.ly/2uI5Pel pic.twitter.com/WVb0m55Ri0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Regeneron proslijedio/la je Tweet
Our partners
@SanofiUS and@Regeneron are committed to empowering patients through education about the science and human impact of disease. At#TEDMED 2020, they will explore how type 2 inflammation may underlie seemingly unconnected diseases such as#asthma and#atopicdermatitispic.twitter.com/OVPWFY6loX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We can’t resist a good meme.
#DollyPartonChallengepic.twitter.com/hbSCWysdfA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#DYK the Regeneron International Science and Engineering Fair receives more than 175,000 applications from students around the world each year, making it is the world’s largest pre-college science and engineering competition? Learn more: http://bit.ly/2RNPeh7 .#RegeneronISEFpic.twitter.com/QXGVuLKVCv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Regeneron proslijedio/la je Tweet
Mark your calendars!
Here's your chance to meet this year's #RegeneronSTS finalists & their amazing
science research projects 
! https://www.facebook.com/events/622177831850956/ …pic.twitter.com/Ns0dDvNuNcOvo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A warm welcome to the 2020
#RegeneronSTS finalists! We’re proud to add 40 more to this family of bright young science heroes.https://twitter.com/Society4Science/status/1220103848624381953 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to our President and CEO Len Schleifer for being included on
@CityAndStateNY’s Health Power 100 list for his leadership in the#biopharma industry. Find out more: http://bit.ly/2TVr9bd .Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.